Pédiatrie Tumeurs solides CPZP034X2203 (VEG116731) A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors. Paris ISABELLE AERTS
Sein métastatique triple négatif IMPASSION 131 (MO39196) A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer Paris DELPHINE LOIRAT
Sein métastatique RH+ PADA-1 Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Recherches "plusieurs pathologies" SHIVA02 (IC 2016-06) Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
Gynécologie - Endomètre ENDOLA A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients Paris MANUEL RODRIGUES
Sein métastatique triple négatif ASCENT (IMMU-132-05) Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer. Paris, Saint-Cloud DELPHINE LOIRAT, FLORENCE LEREBOURS
Recherches "plusieurs pathologies" CHECK'UP Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists. Paris
Sein métastatique triple négatif CO40151 A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer Paris